TNDMTandem Diabetes Care, Inc.

$21.35

TNDM as reported

Tandem Diabetes Care, Inc. reported $1.03B of revenue over the trailing twelve months, +4.5% on the year before. 10 reported series are charted on this page, each one as filed.

$1.03B

Revenue, trailing twelve months · to Q1 2026 · +4.5% against the twelve months before

Net Income
−$95M

Net Income · −49% year on year · trailing twelve months to Q1 2026

Free Cash Flow
−$3.6M

Free Cash Flow · −4.1% year on year · trailing twelve months to Q1 2026

Op Margin
−8.7%

Op Margin · trailing twelve months to Q1 2026

Every series Ryufin has for TNDM, trailing twelve months
SeriesLatestYear on yearAs of
Revenue$1.03B+4.5%Q1 2026
Net Income−$95M−49%Q1 2026
EPS−$1.40−50%Q1 2026
Gross Margin55%n/aQ1 2026
Op Margin−8.7%n/aQ1 2026
Net Margin−9.7%n/aQ1 2026
ROE−128%n/aQ1 2026
ROA−20%n/aQ1 2026
ROIC−94%n/aQ1 2026
Free Cash Flow−$3.6M−4.1%Q1 2026

Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.

Revenue & ProfitTandem Diabetes Care, Inc. (TNDM)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com